VA GLP-1 Coverage for Weight Loss (2026)
If you get your care through the VA, you have probably heard two different stories about GLP-1 medications. One veteran says the VA prescribed one for weight loss. Another says the answer was no. Both can be true, because the VA does not treat these medications as routine formulary drugs for weight loss. It uses national criteria, and whether you meet them depends on what is documented in your chart.
Here is what the VA’s own formulary and pharmacy documents say as of 2026-10-16, and how to find out where you stand.
Transformation Health is an independent guide, not a provider, and is not affiliated with the U.S. Department of Veterans Affairs: we do not prescribe, sell medication, or work with insurance. This content is for general education and is not medical advice. Talk with a licensed provider about your situation.
The short answer
The VA is not an insurance company. If you are enrolled in VA health care, your medications come through the VA pharmacy under the VA National Formulary. As of 2026-10-16, the formulary lists Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide), and Foundayo (orforglipron) as non-formulary.[1]
Non-formulary does not mean never. VA Pharmacy Benefits Management Services (PBM) and the National Formulary Committee publish national criteria for use for Wegovy and for Zepbound for chronic weight management.[2][3] A VA prescriber can request one of them for a veteran who meets those criteria. The VA’s MOVE! program site also says the VA offers weight management medicines, used along with MOVE!.[5]
GLP-1 medications prescribed for type 2 diabetes are a separate category with their own criteria. This page is about weight management.
How GLP-1 access works at the VA
The VA runs one national formulary rather than plan-by-plan drug lists. Each product carries a status. The VA’s own clinical guidance uses these labels: formulary, formulary with prior authorization at the facility level (PA-F), and non-formulary (NF).[4]
| Question | What the VA’s published documents say (as of 2026-10-16) |
|---|---|
| Is Wegovy on the VA National Formulary? | No. Listed as non-formulary[1] |
| Is Zepbound on the VA National Formulary? | No. Listed as non-formulary[1] |
| Saxenda and Foundayo? | Both listed as non-formulary[1] |
| Is there a national path to get Wegovy or Zepbound for weight management? | Yes. VA PBM criteria for use, both revised April 2026[2][3] |
| Lifestyle requirement | Documented participation in a comprehensive lifestyle intervention covering diet, physical activity, and behavior change, at least once within the past year; MOVE! is one example[2][3] |
| BMI requirement | BMI of 27 or higher with at least one weight-related condition[2][3] |
| Examples of weight-related conditions | High blood pressure, type 2 diabetes, prediabetes, high cholesterol, metabolic syndrome, obstructive sleep apnea, osteoarthritis, fatty liver disease (MASLD), heart failure with preserved ejection fraction; Zepbound’s criteria also list prior heart attack, prior stroke, or symptomatic peripheral artery disease[2][3] |
| Exclusions listed | Pregnancy, breastfeeding, type 1 diabetes (with a specialist exception), personal or family history of medullary thyroid carcinoma or MEN 2, severe gastroparesis, certain pancreatitis history, and certain diabetic eye disease without a documented plan[2][3] |
| Who decides exceptions? | Your local VA facility, under its pharmacy and therapeutics committee policies[2][3] |
Two points stand out. First, the request comes from your VA prescriber, so the conversation with your care team is where it starts. Second, the BMI rule as written in both documents is 27 or higher with at least one weight-related condition, so make sure any condition you have is recorded in your chart.
Continuing the medication. The VA’s June 2026 clinical recommendations say clinically meaningful weight loss is generally about 5 percent of baseline body weight, and that if it is not reached after 3 months on the highest dose you can tolerate, or is not maintained, the medication should be stopped. They also say documented ongoing lifestyle program participation is not specifically required for refills.[4]
Diabetes is handled separately. As of 2026-10-16, the formulary lists Ozempic (semaglutide) and Mounjaro (tirzepatide) as formulary with facility-level prior authorization.[1] Both weight management criteria documents say patients prescribed those products for type 2 diabetes fall under separate diabetes criteria for use.[2][3]
Heart disease and sleep apnea. Wegovy is FDA-approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and Zepbound is FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity.[6][7] In the VA’s criteria, these conditions appear as weight-related conditions under the same weight management criteria for use, not as a separate formulary route.[2][3]
Where MOVE! fits in
MOVE! is the VA’s weight management program for veterans, supported by the VA National Center for Health Promotion and Disease Prevention.[5] The VA’s June 2026 clinical recommendations say weight management medications should be prescribed together with a comprehensive lifestyle intervention, and that they may be started at any time during participation, not only after a program is finished.[4]
The same document lists ways MOVE! can count: MOVE! group or individual sessions (in person, phone, or video), TeleMOVE! home telehealth, and self-management tools such as the MOVE! Coach app when used with clinician contact. It says self-management tools without clinician contact, and routine lifestyle advice without a structured curriculum, do not meet the definition.[4] Ask your care team which option your facility offers and make sure your participation is documented.
VA health care, TRICARE, and CHAMPVA are different programs
These names get mixed up, and the drug rules differ by program.
- VA health care is for eligible veterans enrolled with the VA. This page covers it.
- TRICARE is the Defense Department’s health program for service members and their families.[8] See our page on TRICARE GLP-1 coverage.
- CHAMPVA is a VA cost-sharing program for certain spouses, dependent children, and survivors of veterans with a permanent and total service-connected disability, or who died from a service-connected disability. People who are eligible for TRICARE cannot get CHAMPVA.[8] CHAMPVA has its own coverage rules, so check with CHAMPVA directly about weight management medications.
If you also have Medicare or other insurance. Many veterans also carry Medicare, an employer plan, or a marketplace plan, and each follows its own rules. Federal law lets Medicare Part D exclude drugs used for weight loss, and CMS is running the Medicare GLP-1 Bridge from July 1, 2026 through December 31, 2027 for eligible Part D enrollees. Our pages on Medicare Part D and GLP-1 coverage and the Medicare GLP-1 Bridge cover the details. For employer and individual plans, see what insurance covers for weight loss medications.
How to find out where you stand
You do not need to guess. Three steps:
Talk with your VA primary care team. Ask whether you meet the VA criteria for use for Wegovy or Zepbound for weight management, and what is missing from your chart if not. Ask whether any weight-related condition you have, such as high blood pressure, prediabetes, or sleep apnea, is documented. If you have sleep apnea symptoms that were never evaluated, say so.
Ask about MOVE!. If you have not taken part in a lifestyle program in the past year, ask to join MOVE! or another option that counts, and ask that your participation be recorded.
Ask your VA pharmacy or call VA. Your VA pharmacy can tell you how your facility handles non-formulary requests. For questions about signing up for VA health care, va.gov lists a toll-free hotline at 877-222-8387.[9] VA says some veterans receive care at no cost and others have copayments depending on eligibility and priority group, so ask about your own costs.[10]
If the answer is no
What you do next depends on the reason.
A criterion was not met. This is often fixable. Ask your prescriber which item was missing, whether that is lifestyle program documentation, a BMI record, or a weight-related condition, and whether a new request makes sense once it is addressed. The VA criteria say exceptions to the criteria are decided at your local facility under its pharmacy policies, so ask how your facility handles them.[2][3] The general documentation tips in our guide on what to do when a GLP-1 is denied can help you prepare.
An exclusion applies. The exclusions in the criteria, such as pregnancy or a history of medullary thyroid carcinoma, are safety limits that also appear in the product labels. Talk with your VA care team about other options that fit your health.
You want to look outside the VA. Options include:
- Other coverage you have. An employer plan, a spouse’s plan, or Medicare may have different rules. Call the member services number on that card.
- Manufacturer savings and self-pay options. Novo Nordisk and Eli Lilly each publish savings and self-pay terms, and the terms change. Our page on GLP-1 savings programs compares them.
- Cash-pay telehealth programs. Some prescribe brand-name medications and some prescribe compounded medications. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products.[11] Our page on compounded GLP-1 without insurance explains how that route works.
Prices vary by program, medication, and dose. Compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms. At most telehealth programs, a licensed provider reviews your health history and decides whether a prescription is appropriate. If you get medication outside the VA, tell your VA care team so your records stay complete. The full insurance coverage overview can help you weigh the options side by side.
Transformation Health does not accept payment from providers. How we make money.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedCitations
[1] U.S. Department of Veterans Affairs. VA Formulary Advisor, VA National Formulary data (entries for semaglutide, tirzepatide, liraglutide, and orforglipron). Accessed 2026-10-16. https://www.va.gov/formularyadvisor/
[2] VA Pharmacy Benefits Management Services and National Formulary Committee. “Semaglutide (WEGOVY) Subcutaneous Injection and Oral Tablet for Weight Management Criteria for Use.” April 2026. Accessed 2026-10-16. https://www.va.gov/formularyadvisor/DOC_PDF/CFU_Semaglutide_WEGOVY_for_weight_management_CFU_Rev_Apr_2026.pdf
[3] VA Pharmacy Benefits Management Services and National Formulary Committee. “Tirzepatide (ZEPBOUND) Subcutaneous Injection for Weight Management Criteria for Use.” April 2026. Accessed 2026-10-16. https://www.va.gov/formularyadvisor/DOC_PDF/CFU_Tirzepatide_ZEPBOUND_for_weight_management_CFU_Rev_April_2026.pdf
[4] VA Pharmacy Benefits Management Services and National Formulary Committee. “Weight Management Medications for Chronic Use: Clinical Recommendations for Treatment Selection.” June 2026. Accessed 2026-10-16. https://www.va.gov/formularyadvisor/DOC_PDF/CRE_Weight_Management_Medications_Clinical_Recommendations_Rev_June_2026.pdf
[5] U.S. Department of Veterans Affairs, National Center for Health Promotion and Disease Prevention. “MOVE! Weight Management Program.” Last updated October 16, 2026. Accessed 2026-10-16. https://www.move.va.gov/
[6] Novo Nordisk. WEGOVY (semaglutide) prescribing information. Revised 06/2026. Accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
[7] Eli Lilly and Company. ZEPBOUND (tirzepatide) prescribing information. Revised 08/2026. Accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
[8] U.S. Department of Veterans Affairs. “CHAMPVA benefits.” Accessed 2026-10-16. https://www.va.gov/family-and-caregiver-benefits/health-and-disability/champva/
[9] U.S. Department of Veterans Affairs. “How to apply for VA health care.” Accessed 2026-10-16. https://www.va.gov/health-care/how-to-apply/
[10] U.S. Department of Veterans Affairs. “About VA health benefits.” Accessed 2026-10-16. https://www.va.gov/health-care/about-va-health-benefits/
[11] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Accessed 2026-10-16. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Important disclosures
Coverage information on this page is current as of 2026-10-16, is general and educational, and changes frequently. VA criteria for use documents are revised over time. This page does not represent a determination about your eligibility or benefits and is not legal advice. Confirm current formulary status, criteria, and your own options with your VA primary care team or VA pharmacy.
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. A licensed provider decides whether a prescription is appropriate. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound and may differ in formulation, purity, and potency. Wegovy, Ozempic, and Saxenda are trademarks of Novo Nordisk A/S. Zepbound, Mounjaro, and Foundayo are trademarks of Eli Lilly and Company. MOVE!, CHAMPVA, and TRICARE are marks of their respective owners. Transformation Health is not affiliated with or endorsed by the U.S. Department of Veterans Affairs, the Department of Defense, Novo Nordisk, or Eli Lilly. Transformation Health does not accept payment from providers. How we make money.